Jump to the main content block

翁芸芳(Ueng, Yune-Fang)

Ueng, Yune-FangCurrent position: Research Fellow/Chief, Division of Basic Chinese Medicine
E-mail: ueng@nricm.edu.tw


Ph.D., Institute of Biochemistry, School of Medicine, National Taiwan University


Major Professional Experiences
Postdoctoral Associate Research Fellow, Institute of Toxicology, School of Medicine, National Taiwan University
Postdoctoral Research Fellow, Department of Biochemistry and Center of Molecular Toxicology, School of Medicine, Vanderbilt University, TN, U.S.A


Other Experiences
Officer of Toxicology Society of Taiwan
Editor of Pharmacology Newsletter
Member of Toxicology Society of Taiwan
Member of the Pharmacology Society in Taiwan


Academic Honors
The Phi Tau Phi Scholastic Honor Society
The Academic Award of Poison Contro


Drug Metabolism, Biochemical Toxicology, Pharmacy


Research Description
Drug-metabolizing enzymes play important roles in the bioactivation and detoxication of xenobiotics including natural products, drugs, and environmental pollutants. To provide important information for the use of natural products, our research work mainly comprises (1) to determine the effects of natural product on drug-metabolizing enzymes (2) to analyze the metabolites of natural products and to identify the main drug-metabolizing enzymes involved in the natural product metabolism.


Published Papers
NCBI PubMed :  Yune-Fang Ueng (Please click!!)
  1. Selected Publications:

    1. Pan, S. Y., Chi, K. H., Wang, Y.-C., Wei, W.-C., and Ueng, Y.-F.* (2022) Sub-toxic events induced by truck speed-facilitated PM2.5 in A549 human lung cells: counteraction by epigallocatechin-3-gallate. Sci. Report., in press.
    2. Wang, H.-J., Tan, E. C.-H., Chiang, T.-Y., Chen, W.-C., Shen, C.-C., and Ueng, Y.-F.* (2022) Effect of repeated Shengmai-San administration on nifedipine pharmacokinetics and the risk/benefit under co-treatment. J. Food Drug Anal. 30, 111-127.
    3. Chiang, T.-Y., Wang, H.-J., Wang, Y.-C., Tan, E. C.-H., Lee, I-J., Yun, C.-H., and Ueng, Y.-F.* (2021) Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats. J. Ethnopharmacol., 271, 113914.
    4. Huang, C.-T., Tseng, L.-M., Chen, J.-L., Chu, P.-Y., Lee, C.-H., Huang, C.-T., Wang, W.-L., Lau, K.-Y., Tseng, M.-F., Chang, Y.-Y., Chiang, T.-Y., Ueng, Y.-F., Lee, H.-C., Dai, M.-S., and Liu, C.-Y.* (2020) Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression. EBioMedicine 54, 102717.
    5. Ueng, Y.-F.a, Wang, H.-J.a, Wu, S. C., and Ng, Y.-Y.* (2019) A thrice weekly ertapenem is practical for hemodialysis patients. Antimicrobial Agent. Chemother., 63, e01427-19, 1-7.
    6. Chao, T.-C., Pan, W.-C., Tsai, Y.-F., Chou, Y.-C., Liu, Y.-R., Wang, S.-F., Chen, Y.-J., Souček, P., and Ueng, Y.-F.*, Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol. Toxicol. Appl. Pharmacol. 378, 114619, 2019
    7. Lo, S.-N., Wang, C.-W., Chen, Y.-S., Huang, C.-C., Wu, T.-S., Li, L.-A., Lee, I-J., and Ueng, Y.-F.* (2017), Berberine activates aryl hydrocarbon receptor but suppress CYP1A1 induction through miR-21-3p stimulation in MCF-7 breast cancer cells. Molecules, 22, 1847, doi: 10.3390/molecules22111847.
    8. Chen, P.-C., Tsai, W.-J., Ueng, Y.-F., Tzeng, T.-T., Chen, H.-L., Zhu, P.-R., Huang, C.-H., Shiao, Y.-J., Li, W.-T.*(2017) Neuroprotective and anti-neuroinflammatory effects of hydroxyl-functionalized stilbenes and 2-arylbenzo[b]furans. J. Med. Chem., 60, 4062–4073.
    9. Ueng, Y.-F.*, Lu, C.-K., Yang, S.-H., Wang, H.-J., and Huang C.-C. (2017) Potentiation of the anticoagulation effect of warfarin by the herbal remedy Shu-Jing-Hwo-Shiee-Tang in rats: the dosing regimen and pharmacokinetic interaction. Drug Metab. Pharmacokinet., 32, 85-91.
    10. Chang, Y.-P., Huang, C.-C., Shen, C.-C., Tsai, K.-C., and Ueng, Y.-F.* (2015) Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab. Pharmacokinet., 30, 374-383.
    11. Lo, S.-N., Shen, C.-C., Chang, C.-Y., Tsai, K.-C., Huang, C.-C., Wu, T.-S., and Ueng, Y.-F.* (2015) The effect of oxidation on berberine-mediated CYP1 inhibition: oxidation behavior and metabolite-mediated inhibition. Drug Metab. Dispos., 43, 1100-1107.
    12. Lee, K.-H.a, Ueng, Y.-F.aWu, C.-W., Chou, Y.-C., Ng, Y.-Y.*, Yang, W.-C. (2014) The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in hemodialysis patients – case reports and literature reviews. J. Clin. Pharm. Therapeut. doi: 10.1111/jcpt.12239.
    13. Lo, S.-N., Chang, Y.-P., Tsai, K.-C., Chang, C.-Y., Wu, T.-S.**, and Ueng, Y.-F.* (2013) Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol. Appl. Pharmacol., 272, 671-680.
    14. Wang, S.-F., Chou, Y.-C., Mazumder, N., Kao, F.-J., Nagy L. D., Guengerich, F. P., Huang, C., Lee, H.-C., Lai, P.-S., and Ueng, Y.-F.* (2013) 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells. Biochem. Pharmacol., 86,548-560.
    15. Ueng, Y.-F.*, Chen, C.-C., Yamazaki, H., Kiyotani, K., Chang, Y.-P., Lo, W.-S., Li, D.-T., and Tsai, P.-L. (2013) Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metab. Pharmacokinet. 28, 229-238.
    16. Lo W.-S., Lim Y.-P., Chen, C.-C., Hsu, C.-C., Souček, P., Yun, C.-H., Xie, W., and Ueng Y.-F.* (2012) A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation. Arch. Toxicol., 86, 1927-1938.
    17. Souček, P., Kondrová, E., Heřmánek, J., Stopka, P., Boumendjel, A., Ueng, Y.-F., and Gut, I. (2011). New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anti-cancer Drugs, 22(2), 176-184. doi:10.1097/CAD.0b013e328341a17b
    18. Ueng, Y.-F., Chen, C.-C., Chung, Y.-T., Liu, T.-Y., Chang, Y.-P., Lo, W.-S., Li, D.-T. (2011). Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. British Journal of Pharmacology, 163(6), 1250-1262. doi:10.1111/j.1476-5381.2011.01341.x
    19. Ueng, Y.F* Tsai, C.C., Lo, W.S., Yun, C.H. (2010) Induction of hepatic cytochrome P450s by the herbal medicine, Sophora flavescens extract in rats: the impact on the elimination of theophylline. Drug Metab. Pharmacokinet.,25:560–567.
    20. Chou, Y.C., Lin, M.H., Chung, Y.T., Liu, T.Y., Wang, S.Y., Chau, G.Y., Chi, C.W., Lee,C.H., Souček, P.,Krausz, K., Gelboin, H.V., and Ueng, Y.F.* (2010) The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J. Pharm. Sci., 99, 1063-1077.
    21. Ueng, Y.F.*, Chen, C.C., and Tsai, C.C. (2009) Differential inductive profiles of  hepatic cytochrome P450s by the extracts of Sophora flavescens in male and female C57BL/6JNarl mice. J. Ethnopharmacol., 126,437-446.
    22. Pan, W.C., Chen, R.M., Shen, Y.C., Chen, C.C., and Ueng, Y.F.* (2009) Suppressive effect of tobacco smoke extracts on oral P-glycoprotein function and its impact in smoke-induced insult to oral epidermal cells. Toxicol. Lett., 185, 116-123.
    23. Wu G.J., Chen T.L., Ueng Y.F., and Chen R.M.* (2008) Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharidestimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol., 228, 105-113.
    24. Su C.R., Ueng Y.F., Dung N.X., Reddy V.B., and Wu T.S. (2007) Cytochrome P450 3A4 inhibitors and other constituents of Fibraurea tinctoria. J. Nat. Prod., 70, 1930-1933.
    25. Ueng Y.F.*, Jan W.C., Don M.J., Ho L.K., and Chen C.F. (2006) Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450s. Drug Metab. Dispos., 34, 821-827.
    26. Kuo Y.H., Lin Y.L., Don M.j., Chen R.M., and Ueng Y.F.*(2006) Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J. Pharm. Pharmacol., 58, 521-527
    27. Ueng Y.F.*, Yu H.J., Lee C.H., Peng C., Jan W.C., Ho L.K., Chen C.F., and Don M.J.* (2005) Identification of the microsomal oxidation metabolites of rutaecarpine, a main active alkaloid of the medicinal herb Evodia rutaecarpa. J. Chromatogr. A, 1076, 103-109
    28. Ueng Y.F.*, Chieh C.H., and Don M.J. (2005) Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem. Toxicol., 43, 707-712.
    29. Ueng, Y.-F.*, Hsieh, C.-H., Don, M.-J. and Ho, L.-K. (2004) Identification of the main cytochrome P450 involved in safrole 1’-hydroxylation. Chem. Res. Toxicol.,17, 1151-1156.
    30. Ueng, Y.-F.*, Jan, W.-C., Lin, L.-C., Chen, T.-L., Guengerich, F. P., and Chen, C.-F. (2002) The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab. Dispos., 30, 349-353.
    31. Ueng, Y.-F.*, Shyu, C.-C., Liu, T.-Y., Oda, Y., Lin, Y.-L., Liao, J.-F., and Chen, C.-F. (2001) Protective effects of baicalein and wogonin against benzo(a)pyrene and aflatoxin B1-induced genotoxicities. Biochem. Pharmacol. 62, 1653-1660.
    32. Ueng, Y.-F., Shimada, T., Yamazaki, H., and Guengerich, F. P.* (1998) Aflatoxin B1 oxidation by human cytochrome P450s. J. Toxicol. Sci., 23, Suppl. II, 132-135.
    33. Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., and Guengerich, F. P.* (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36: 370-381.
    34. Ueng, Y.-F., Shimada, T., Yamazaki, H., and Guengerich, F. P.* (1995), Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8: 218-225.


Click Num: